Skip to main content

Advertisement

SpringerLink
Log in

Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Immunotherapy is being increasingly utilized for adjuvant treatment for breast cancer (BC). We have previously described immune functions during primary therapy for BC. The present study describes immune recovery patterns during long-term, unmaintained follow-up after completion of adjuvant therapy.A group of patients with primary BC had been treated with adjuvant radio-chemotherapy (RT + CT) 5-fluorouracil, epirubicin and cyclophosphamide (FEC) (n = 21) and another group with radiotherapy (RT) (n = 20) alone. Immunological testing of NK and T-cell functions was performed initially at the end of adjuvant treatment and repeated after 2, 6 and 12 months. NK cell cytotoxicity was significantly higher (P < 0.05) at all time-points in patients than in age-matched controls and did not differ between the two treatments groups during one year observation. In contrast, lower numbers of CD4 T-cells and lower expression of CD28 on T-cells was observed particularly in RT + CT patients and did not normalize during the observation period. The numbers of Treg cells (CD4+CD25high) were low in the RT + CT group during follow-up, as well as expression of TCRξ, Zap70, p56lck, P59fyn and PI3 k in CD4+ cells. In contrast, expression of intracellular cytokines (IFN-γ, IL-2, IL-4) in CD4 and CD8 T cells were significantly higher in RT + CT patients than in the RT group and the difference increased during follow-up. In conclusion, NK-cell cytotoxicity increased during unmaintained long-term follow-up whereas CD4 and regulatory T cells as well as signal transduction molecules remained low following adjuvant radio-chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, Jeannin JF, Coudert B (2006) Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94:259–267

    Article  PubMed  CAS  Google Scholar 

  2. Asavaroengchai W, Kotera Y, Mule JJ (2002) Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci USA 99:931–936

    Article  PubMed  CAS  Google Scholar 

  3. Baral E, Nagy E, Berczi I (1995) Modulation of natural killer cell-mediated cytotoxicity by tamoxifen and estradiol. Cancer 75:591–599

    Article  PubMed  CAS  Google Scholar 

  4. Ben-David H, Sharabi A, Dayan M, Sela M, Mozes E (2007) The role of CD8+CD28 regulatory cells in suppressing myasthenia gravis-associated responses by a dual altered peptide ligand. Proc Natl Acad Sci USA 104:17459–17464

    Article  PubMed  CAS  Google Scholar 

  5. Carson WE, Parihar R, Lindemann MJ, Personeni N, Dierksheide J, Meropol NJ, Baselga J, Caligiuri MA (2001) Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol 31:3016–3025

    Article  PubMed  CAS  Google Scholar 

  6. Cheda A, Nowosielska EM, Wrembel-Wargocka J, Janiak MK (2008) Production of cytokines by peritoneal macrophages and splenocytes after exposures of mice to low doses of X-rays. Radiat Environ Biophys 47(2):275–283

    Article  PubMed  CAS  Google Scholar 

  7. Cheng F, Gabrilovich D, Sotomayor EM (2004) Immune tolerance in breast cancer. Breast Dis 20:93–103

    PubMed  CAS  Google Scholar 

  8. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443–446

    Article  PubMed  CAS  Google Scholar 

  9. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K (2002) Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20:2624–2632

    Article  PubMed  CAS  Google Scholar 

  10. Fattorossi A, Battaglia A, Ferrandina G, Coronetta F, Legge F, Salutari V, Scambia G (2004) Neoadjuvant therapy changes the lymphocyte composition of tumor-draining lymph nodes in cervical carcinoma. Cancer 100:1418–1428

    Article  PubMed  CAS  Google Scholar 

  11. Filaci G, Fenoglio D, Fravega M, Ansaldo G, Borgonovo G, Traverso P, Villaggio B, Ferrera A, Kunkl A, Rizzi M, Ferrera F, Balestra P, Ghio M, Contini P, Setti M, Olive D, Azzarone B, Carmignani G, Ravetti JL, Torre G, Indiveri F (2007) CD8+ CD28− T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J Immunol 179:4323–4334

    PubMed  CAS  Google Scholar 

  12. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, Villani L, Magalotti C, Gibelli N, Oliviero B, Ballardini B, Da Prada G, Zambelli A, Costa A (2004) Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10:5650–5655

    Article  PubMed  CAS  Google Scholar 

  13. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B (2007) Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56:641–648

    Article  PubMed  CAS  Google Scholar 

  14. Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ (2006) Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist 11:857–867

    Article  PubMed  CAS  Google Scholar 

  15. Hellman C, Lonnkvist K, Hedlin G, Hallden G, Lundahl J (2002) Down-regulated IL-5 receptor expression on peripheral blood eosinophils from budesonide-treated children with asthma. Allergy 57:323–328

    Article  PubMed  CAS  Google Scholar 

  16. Hjelm Skog AL, Wadhwa M, Hassan M, Gharizadeh B, Bird C, Ragnhammar P, Thorpe R, Mellstedt H (2001) Alteration of interleukin 2 (IL-2) pharmacokinetics and function by IL-2 antibodies induced after treatment of colorectal carcinoma patients with a combination of monoclonal antibody 17-1A, granulocyte macrophage colony-stimulating factor, and IL-2. Clin Cancer Res 7:1163–1170

    PubMed  CAS  Google Scholar 

  17. Kochenderfer JN, Simpson JL, Chien CD, Gress RE (2007) Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific anti-tumor immunity from T cell populations undergoing homeostatic peripheral expansion after BMT. Blood 110(1):450–460

    Article  PubMed  CAS  Google Scholar 

  18. Kurt RA, Urba WJ, Smith JW, Schoof DD (1998) Peripheral T lymphocytes from women with breast cancer exhibit abnormal protein expression of several signaling molecules. Int J Cancer 78:16–20

    Article  PubMed  CAS  Google Scholar 

  19. Kuss I, Donnenberg AD, Gooding W, Whiteside TL (2003) Effector CD8+CD45RO-CD27-T cells have signalling defects in patients with squamous cell carcinoma of the head and neck. Br J Cancer 88:223–230

    Article  PubMed  CAS  Google Scholar 

  20. Liu JY, Wu Y, Zhang XS, Yang JL, Li HL, Mao YQ, Wang Y, Cheng X, Li YQ, Xia JC, Masucci M, Zeng YX (2007) Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol Immunother 56:1597–1604

    Article  PubMed  CAS  Google Scholar 

  21. Lukac J, Kusic Z, Kordic D, Koncar M, Bolanca A (1994) Natural killer cell activity, phagocytosis, and number of peripheral blood cells in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 29:279–285

    Article  PubMed  CAS  Google Scholar 

  22. Mozaffari F, Hansson L, Kiaii S, Ju X, Rossmann ED, Rabbani H, Mellstedt H, Osterborg A (2004) Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage. Br J Haematol 124:315–324

    Article  PubMed  CAS  Google Scholar 

  23. Mozaffari F, Lindemalm C, Choudhury A, Granstam-Bjorneklett H, Helander I, Lekander M, Mikaelsson E, Nilsson B, Ojutkangas ML, Osterborg A, Bergkvist L, Mellstedt H (2007) NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy. Br J Cancer 97:105–111

    Article  PubMed  CAS  Google Scholar 

  24. Murta EF, de Andrade JM, Falcao RP, Bighetti S (2000) Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy. Tumori 86:403–407

    PubMed  CAS  Google Scholar 

  25. Nahta R, Esteva FJ (2006) HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 8:215

    Article  PubMed  Google Scholar 

  26. Orditura M, Romano C, De Vita F, Galizia G, Lieto E, Infusino S, De Cataldis G, Catalano G (2000) Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival. Cancer Immunol Immunother 49:530–536

    Article  PubMed  CAS  Google Scholar 

  27. Proietti E, Greco G, Garrone B, Baccarini S, Mauri C, Venditti M, Carlei D, Belardelli F (1998) Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J Clin Invest 101:429–441

    Article  PubMed  CAS  Google Scholar 

  28. Repka T, Chiorean EG, Gay J, Herwig KE, Kohl VK, Yee D, Miller JS (2003) Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. Clin Cancer Res 9:2440–2446

    PubMed  CAS  Google Scholar 

  29. Robinson E, Rubin D, Mekori T, Segal R, Pollack S (1993) In vivo modulation of natural killer cell activity by tamoxifen in patients with bilateral primary breast cancer. Cancer Immunol Immunother 37:209–212

    Article  PubMed  CAS  Google Scholar 

  30. Schiavoni G, Mattei F, Di Pucchio T, Santini SM, Bracci L, Belardelli F, Proietti E (2000) Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 95:2024–2030

    PubMed  CAS  Google Scholar 

  31. Shan YX, Jin SZ, Liu XD, Liu Y, Liu SZ (2007) Ionizing radiation stimulates secretion of pro-inflammatory cytokines: dose-response relationship, mechanisms and implications. Radiat Environ Biophys 46:21–29

    Article  PubMed  CAS  Google Scholar 

  32. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sanchez Rovira P, Piccart-Gebhart MJ (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369:29–36

    Article  PubMed  CAS  Google Scholar 

  33. Solomayer EF, Feuerer M, Bai L, Umansky V, Beckhove P, Meyberg GC, Bastert G, Schirrmacher V, Diel IJ (2003) Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer. Clin Cancer Res 9:174–180

    PubMed  CAS  Google Scholar 

  34. Tripathy D (2005) Targeted therapies in breast cancer. Breast J 11(Suppl 1):S30–S35

    Article  PubMed  Google Scholar 

  35. Valabrega G, Montemurro F, Aglietta M (2007) Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 18:977–984

    Article  PubMed  CAS  Google Scholar 

  36. Wasserman J, Blomgren H, Rotstein S, Petrini B, Hammarstrom S (1989) Immunosuppression in irradiated breast cancer patients: in vitro effect of cyclooxygenase inhibitors. Bull N Y Acad Med 65:36–44

    PubMed  CAS  Google Scholar 

  37. Weiner LM, Adams GP (2000) New approaches to antibody therapy. Oncogene 19:6144–6151

    Article  PubMed  CAS  Google Scholar 

  38. Yi H, Rong Y, Yankai Z, Wentao L, Hongxia Z, Jie W, Rongyue C, Taiming L, Jingjing L (2006) Improved efficacy of DNA vaccination against breast cancer by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65. Vaccine 24:2575–2584

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by grants from Sparbanksstiftelsen Nya Västerås, Cancer and Allergy Foundation, The Research Foundation of Västmanland, Cancer and Traffic Injury Fund, and the County Council of Västmanland. We thank Ms. Birgitta Hagström for her expert technical assistance and Ms. Leila Relander for help with preparing the manuscript.

Author information

Authors and Affiliations

  1. Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Karolinska University Hospital Solna, Stockholm, Sweden

    Fariba Mozaffari, Christina Lindemalm, Aniruddha Choudhury, Anders Österborg & Håkan Mellstedt

  2. Department of Oncology, Central Hospital, Västerås, Sweden

    Helena Granstam-Björneklett

  3. Department of Clinical Neuroscience, Osher Center for Integrative Medicine and Section of Psychology, Karolinska Institutet, Stockholm, Sweden

    Mats Lekander

  4. Department of Cancer Epidemiology, Karolinska University Hospital Solna, Stockholm, Sweden

    Bo Nilsson

  5. Centre for Clinical Research, Uppsala University, Central Hospital, Västerås, Sweden

    Marja-Leena Ojutkangas & Leif Bergkvist

  6. Departments of Hematology and Oncology, Karolinska University Hospital Solna, Stockholm, Sweden

    Anders Österborg & Håkan Mellstedt

  7. Department of Surgery, Central Hospital, Västerås, Sweden

    Leif Bergkvist

  8. Department of Oncology (Radiumhemmet), Karolinska University Hospital, 171 76, Stockholm, Sweden

    Håkan Mellstedt

Authors
  1. Fariba Mozaffari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christina Lindemalm
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aniruddha Choudhury
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Helena Granstam-Björneklett
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mats Lekander
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bo Nilsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marja-Leena Ojutkangas
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Anders Österborg
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Leif Bergkvist
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Håkan Mellstedt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Håkan Mellstedt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mozaffari, F., Lindemalm, C., Choudhury, A. et al. Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study. Cancer Immunol Immunother 58, 111–120 (2009). https://doi.org/10.1007/s00262-008-0530-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-008-0530-5

Keywords

Search

Navigation